Cardiovascular • May 1-3, 2017
Boston, MA • United States

Agenda

Monday, May 1, 2017

7:00 am - 8:00 am
8:00 am - 11:30 am
Pfizer Ballroom
First Look: The Next Wave of Cardiology Breakthroughs

Harvard Medical School investigators describe their most promising work in rapid fire presentations highlighting commercial opportunities in cardiovascular and cardiometabolic care. Twenty rising stars from Brigham and Women’s Hospital and Massachusetts General Hospital will present in 10-minute sessions.

11:45 am - 1:15 pm
7th Floor
Concurrent Discovery Cafés Breakout Sessions: Sharing Perspectives

Top Cardiology faculty from Brigham and Women’s Hospital and Massachusetts General Hospital address compelling topics in clinical research and implementation of care. Lunch to be provided.

Topics to be covered include:

  • Cardiac Replacement Therapy: The Next Ten Years
  • Heart Failure: Back in The Game through New Pathways
  • Payment Models: Provider’s Perspective
  • Molecular Imaging: New Biological Endpoints – Function Over Structure
  • Open Innovation in Medical Devices: What is it? What Are the Barriers?
  • Wearables for Cardiovascular Health:  How to Validate and Integrate in Care Paths?
  • Image Based Artificial Intelligence: Which Cardiac Disease Segments and Why?

 

1:15 pm - 1:30 pm
1:30 pm - 1:35 pm
Boston Scientific Ballroom
Opening Remarks
Introduction by: Anne Klibanski, MD
  • Chief Academic Officer, Partners HealthCare
  • Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, Harvard Medical School
  • CEO, Partners HealthCare
1:35 pm - 1:55 pm
Boston Scientific Ballroom
Reinventing Cardiac Care

Two renowned clinical leaders provide an overview of the medical and economic challenges that cardiovascular and cardiometabolic disorders present.

They will highlight strategic direction in cardiac research and clinical care at Partners, and address how recent trends in investment, regulation, and policy may be dovetailed with efforts at Partners.

The experts also spotlight for attendees the various therapies, diagnostics, devices, and critical issues that will be discussed throughout the upcoming 2.5 days of the World Medical Innovation Forum.

  • CEO, XTuit Pharmaceuticals
  • Chief of Cardiovascular Medicine, Brigham and Women's Hospital
  • Associate Professor of Medicine, Harvard Medical School
  • Chief, Cardiology Division, Massachusetts General Hospital
  • Professor of Medicine, Harvard Medical School
1:55 pm - 2:45 pm
Boston Scientific Ballroom
CEO Roundtable: Today's Learning, Tomorrow's Opportunities

Discussion on contribution of technology innovation to the treatment of cardiovascular disease reflecting on lessons and how they shape investment decisions.

Moderator: Benjamin Pless
  • Executive in Residence, Partners HealthCare Innovation
  • EVP Medical Affairs and CMO, UnitedHealth Group
  • CEO, Abiomed
  • CEO, Edwards Lifesciences
  • CEO, Bard
2:45 pm - 3:35 pm
Boston Scientific Ballroom
Tackling the AFib Epidemic

Evolving trends in diagnosis, prevention, and treatment of atrial fibrillation. Factors that will influence patient care over the next 5 years are considered, including risk stratification, procedure and technology options, and potential implications of CMS policies, such as bundling.

 

  • Associate Chief, Cardiology Division, Massachusetts General Hospital Heart Center
  • Professor of Medicine, Harvard Medical School
  • Director, Cardiac Arrhythmia Service, Massachusetts General Hospital
  • Associate Professor, Harvard Medical School
  • VP, GM, AF Solutions, Medtronic
  • VP, Global Health Policy, Boston Scientific
  • President, Cardiovascular and Neuromodulation, Abbott
  • VP US Medical Affairs, CVMD TA, AstraZeneca
3:35 pm - 4:05 pm
Boston Scientific Ballroom
1:1 Fireside Chat: Omar Ishrak, PhD, CEO, Medtronic
Moderator: Paul LaViolette
  • Managing Partner & COO, SV Life Sciences Advisers
  • CEO, Medtronic
4:05 pm - 4:55 pm
Boston Scientific Ballroom
Heart Failure's Therapeutic Mandate

One million patients are hospitalized annually for HF—80% of total US cost of HF management. After discharge from HF hospitalization, 24% are rehospitalized within 30 days, greater than 50% within 6 months. Perspective on disease management, addressing the issues of hospital readmission and optimizing therapies.

 

Moderator: Akshay Desai, MD
  • Director, Heart Failure Disease Management, Brigham and Women's Hospital
  • Associate Professor, Harvard Medical School
  • VP and Medical Director, Abbott
  • Global Translational Medicine Head, Novartis Institutes for BioMedical Research, Brigham and Women's Hospital
  • Senior Lecturer, Harvard Medical School
  • CEO, MyoKardia
  • SVP, CMO, Global Health Policy, Rhythm Management, Boston Scientific
4:55 pm - 6:00 pm
Boston Scientific Ballroom
CLINICAL HIGHLIGHT: A New Chapter of PAD

PAD is the most challenging atherosclerotic syndrome, largely due to the technological challenges of managing peripheral artery disease through minimally invasive strategies. Top physician, governmental, and industry leaders in the field discuss the potential for new breakthroughs including novel implantable devices, pharmacologic approaches, and reductions in associated cardiovascular morbidity and mortality.

The panel will also discuss, Below The Knee: The Persisting Unmet Need

 

Moderator: Michael Jaff, DO
  • President, Newton-Wellesley Hospital, Partners Healthcare
  • Professor of Medicine, Harvard Medical School
  • Director, Cardiology and Interventional Cardiology Fellowship Programs, Massachusetts General Hospital
  • Assistant Professor of Medicine, Harvard Medical School
  • Director, Coverage and Analysis Group, CMS
  • Chief, Peripheral Interventional Devices Branch, Food and Drug Administration
  • CMO, Cardinal Health
  • Co-Director, Endovascular Surgery, Brigham and Women's Hospital
  • Assistant Professor, Harvard Medical School
  • SVP and President, Peripheral Interventions, Boston Scientific
6:00 pm - 6:45 pm
Lilly Foyer

Tuesday, May 2, 2017

7:00 am - 7:30 am
Lilly Foyer
7:00 am - 7:45 am
Pfizer Ballroom
FOCUS SESSION: Japan Today: Advancing Cardiometabolic Therapies

Discussion on unique aspects of cardiometabolic market in Japan, its projected trend over the next 5 years and explore transformative models of open innovation to accelerate development of new therapeutic options.

  • Yoshiro Miwa Associate Chair and Founding Director, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital
  • Head of Pharmaceuticals, Americas Region, Bayer
  • Director, Health & Welfare Department, JETRO New York
  • President, Head of Global Development, Mitsubishi Tanabe
7:50 am - 8:00 am
Boston Scientific Ballroom
Opening Remarks
  • Chief Innovation Officer, Partners HealthCare
8:00 am - 8:50 am
Boston Scientific Ballroom
Pricing to Enable Affordability and Innovation

Balancing acceptable answers to high and escalating drug prices in the United States while making strides in medical innovation. Leaders in innovation, policy, care delivery, academia, and insurance discuss potential collaborative solutions.

 

Moderator: Peter Slavin, MD
  • President, Massachusetts General Hospital
  • Physician-in-Chief, Department of Medicine, Massachusetts General Hospital
  • Jackson Professor of Clinical Medicine, Harvard Medical School
  • CEO, Cardinal Health
  • CEO, Boehringer Ingelheim USA
  • Abbott
  • Director of Innovation, Cardiovascular Division, Senior Investigator, TIMI Study Group, Brigham and Women's Hospital
  • Associate Professor of Medicine Harvard Medical School
8:50 am - 9:40 am
Boston Scientific Ballroom
CLINICAL HIGHLIGHT: Emerging Devices for Complex Structural Heart Disease

Evolution of mitral disease management, current practice and impact of new technologies on both repair and replacement, implications of a heterogeneous patient population, triage, timing of intervention.

Moderator: Jason Mills
  • Managing Director, Head of US Healthcare Research, Canaccord Genuity
  • DVP, General Manager, Abbott
  • EVP, Global CMO, Boston Scientific
  • Director, Clinical Cardiology, Executive Medical Director, Brigham and Women's Hospital
  • Professor of Medicine, Harvard Medical School
  • CVP, Advanced Technology, CSO, Edwards Lifesciences
  • SVP and President, Coronary & Structural Heart, Medtronic
9:40 am - 10:10 am
Boston Scientific Ballroom
1:1 Fireside Chat: John Lechleiter, PhD, Chairman, Eli Lilly
Moderator: Susan Dentzer
  • CEO, Network for Excellence in Health Innovation
  • Chairman, Eli Lilly and Company
10:10 am - 10:25 am
Lilly Foyer
10:25 am - 11:15 am
Boston Scientific Ballroom
Personal Monitoring for Disease Management

Considering the evolving trends in viability and utilization and the opportunities wearables may present for real-world clinical decision making.

 

Moderator: Joe Kvedar, MD
  • VP, Connected Health, Partners HealthCare
  • Associate Professor of Dermatology, Harvard Medical School
  • CEO, GE Healthcare
  • CIO, VP, Brigham and Women's Hospital
  • Course Co-Director, Harvard Medical School
  • CEO, Siemens Healthcare
  • CEO, Zoll Medical
  • CSO, One Brave Idea, Brigham and Women's Hospital
  • Associate Dean for Executive Education, Harvard Medical School
11:15 am - 11:45 am
Boston Scientific Ballroom
12:00 pm
GE Ballroom
12:15 pm - 12:30 pm
GE Ballroom
12:30 pm - 1:00 pm
GE Ballroom
1:00 pm - 1:10 pm
1:10 pm - 2:00 pm
Boston Scientific Ballroom
Global Clinical Trials: Next Generation Design and Scalability

Cardiovascular trials currently account for 10 percent of all clinical trial participants. Discussion on design and implementation of clinical studies globally, considering strategies for patient access, regulatory implications, cost containment and management of relationships with global service providers.

 

  • Chairman, TIMI Study Group, Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine, Brigham and Women's Hospital
  • VP, Cardiovascular & Metabolic Disease Head, Global Medicines Development, AstraZeneca
  • SVP, Global Clinical Research, Therapeutic Area Head, Cardiometabolic & Womens Health, MRL Lead, China R&D, Merck & Co.
  • VP Cardiovascular Medicine, Covance
  • Director, Division of Cardiovascular and Renal Products, Food and Drug Administration
  • Vice President, Global Development, Amgen
2:00 pm - 2:50 pm
Boston Scientific Ballroom
Precision Cardiovascular Medicine: What is Different This Time

Explore how precision medicine is changing the face of cardiovascular medicine specifically. The session will examine the impact of combined phenotypic and genotypic characterization on optimizing response to therapeutics, trial design, improving outcomes, and redefining reimbursement.

Moderator: Sue Siegel
  • CEO, GE Ventures & healthymagination
  • EVP, R&D, Amgen
2:50 pm - 3:40 pm
Boston Scientific Ballroom
CV Investing in the Next Decade

View on investing landscape, opportunities in the CV/metabolic marketplace, the drugs, devices and diagnostics currently in pipelines and notable positive trends.

  • Managing Director, Healthcare, GE Ventures
  • Partner, Atlas Venture
  • Managing Director, US Medical Technology, Equity Research, Bank of America Merrill Lynch
  • VP, Venture, Partners HealthCare
  • Managing General Partner, Frazier Healthcare Partners
3:40 pm - 4:30 pm
Boston Scientific Ballroom
CLINICAL HIGHLIGHT: Optimizing Care for the 51%: New Market Opportunities

Introduction: Cathy Minehan, Chair, MGH Corporation

Address implications of gender as a key biological factor for personalized medicine. Stroke is likely to be the first cardiovascular event, tied to AF and secondarily to hypertension. Opportunities for medication utilization and optimization in context of, manifestation of disease and understanding the biology, complications, strategies to collect relevant clinical evidence, and treatment response.

Moderator: Nancy Brown
  • CEO, American Heart Association
  • Director, Center for Arrhythmia Prevention, Brigham and Women's Hospital
  • Mylan
  • CV Therapeutic Area Lead, Global Business Development, Pfizer
  • Medical Director, Boston Scientific
  • Co-Director, MGH Heart Center Corrigan Women's Heart Health Program, Massachusetts General Hospital
  • Associate Professor, Harvard Medical School
4:30 pm - 5:20 pm
Boston Scientific Ballroom
Disruptive Therapeutic Platforms: New Tools, New Outcomes

Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases including heart failure. These emerging drugs could be considered in context of genomic/germ line screening, family history and epigenetics.

Moderator: Tony Coles, MD
  • CEO, Yumanity Therapeutics
  • CEO, Moderna
  • CEO, Editas Medicine
  • CEO, Alnylam
  • Founder, AnGes
5:20 pm - 6:00 pm
Essex Foyer

Wednesday, May 3, 2017

7:00 am - 7:30 am
Lilly Foyer
7:30 am - 7:55 am
Boston Scientific Ballroom
1:1 Fireside Chat: Robert Califf, MD, Commissioner (former), Food and Drug Administration
  • Chairman, Department of Medicine, Physician-in-Chief, Brigham and Women's Hospital
  • Hersey Professor of the Theory and Practice of Medicine, Soma Weiss, MD Distinguished Chair in Medicine, Harvard Medical School
  • Commissioner (former), Food and Drug Administration
7:55 am - 8:45 am
Boston Scientific Ballroom
Innovation in Translational Trials

CV/metabolic disorders comprise aggregates of many niche diseases that may be targeted with therapies against specific molecular alterations, yet the final potential markets are much larger. This model creates challenges for both drug development and patient care with implications for initial indication selection and design and execution of clinical trials – from first-in-human through post marketing studies.

 

  • Director, Translational Research Center, Massachusetts General Hospital
  • Professor of Medicine Harvard Medical School
  • SVP, Global Head of Regenerative Medicine Unit, Head of Scientific Affairs, Japan, Takeda
  • SVP, R&D Pipeline, GlaxoSmithKline
  • CMO, Verily
  • SVP, Global CMO, Novo Nordisk
  • Senior Vice President & CSO, PAREXEL International
8:45 am - 9:15 am
Boston Scientific Ballroom
9:15 am - 10:05 am
Boston Scientific Ballroom
New Targets in Coronary Artery Disease

Cardiovascular trials have a proud history of providing some of the most robust data in evidence-based medicine. However the growing size and complexity of these trials imperils their future. This panel will discuss the design and implementation of clinical studies globally, considering strategies for patient access, leveraging electronic health records and mobile device data, personalized medicine, regulatory implications, cost containment and management of relationships with global service providers.

  • Director, Center for Human Genetic Research, Massachusetts General Hospital
  • Associate Professor of Medicine, Harvard Medical School
  • VP Research, Cardiometabolic Disorders Therapeutic Area Head, Site Head Amgen San Francisco, Amgen
  • CEO, The Medicines Company
  • Director, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital
  • Eugene Braunwald Professor of Medicine, Harvard Medical School
  • CMO, Kowa Pharmaceuticals
10:05 am - 10:25 am
Lilly Foyer
10:25 am - 10:55 am
Boston Scientific Ballroom
1:1 Fireside Chat: Gary Gibbons, MD, NHLBI
  • President, Brigham Health
  • Professor of Medicine, Harvard Medical School
  • Director, NHLBI
10:55 am - 11:45 am
Boston Scientific Ballroom
The Skinny on Fat: Therapeutic Opportunities

Explore the evolving role of adipose tissue as an active endocrine organ and discuss the possibilities to discover novel signaling pathways relevant to cardiovascular health and viable druggable targets.

  • SVP and US Medical Leader, Eli Lilly and Company
  • SVP and CSO, CVMET, Pfizer
  • CEO, Zafgen
  • Director, Obesity, Metabolism & Nutrition Institute, Massachusetts General Hospital
  • Stanley J. Korsmeyer Professor of Cell Biology and Medicine, Dana Farber Cancer Institute, Harvard Medical School
11:45 am - 12:45 pm
Boston Scientific Ballroom
Disruptive Dozen: 12 Technologies that will reinvent Cardiovascular Care
  • Chief of Cardiovascular Medicine, Brigham and Women's Hospital
  • Associate Professor of Medicine, Harvard Medical School
  • Chief, Cardiology Division, Massachusetts General Hospital
  • Professor of Medicine, Harvard Medical School
1:00 pm
Lilly Foyer

*Panels and speakers are subject to change.